Douglas Roeder - Tandem Diabetes Independent Director
| TNDM Stock | USD 30.93 0.82 2.58% |
Director
Mr. Douglas A. Roeder is an Independent Director of Tandem Diabetes Care Inc. Mr. Roeder has served on our board of directors since May 2009. Mr. Roeder joined Delphi Ventures as an Associate in 1998, and was a Partner since 2000, focusing on medical devices, diagnostics and biotechnology. Prior to joining Delphi Ventures, Mr. Roeder was an associate with Alex Browns Healthcare Investment Banking Group in San Francisco, where he focused on the medical device, life sciences and healthcare services industries. Mr. Roeder serves as a director of Senseonics Holdings, Inc., a continuous glucose monitoring company, and several privately held companies. He previously served as a director of Trivascular Technologies, Inc., a medical device company, which was acquired by Endologix, Inc. in February 2016. He also previously worked with Putnam Associates, a strategy consulting firm focused on the pharmaceutical and biotechnology industries. Mr. Roeder holds an A.B. in Biochemistry from Dartmouth College. since 2009.
| Age | 47 |
| Tenure | 15 years |
| Address | 12400 High Bluff Drive, San Diego, CA, United States, 92130 |
| Phone | 858 366 6900 |
| Web | https://www.tandemdiabetes.com |
Douglas Roeder Latest Insider Activity
Tracking and analyzing the buying and selling activities of Douglas Roeder against Tandem Diabetes stock is an integral part of due diligence when investing in Tandem Diabetes. Douglas Roeder insider activity provides valuable insight into whether Tandem Diabetes is net buyers or sellers over its current business cycle. Note, Tandem Diabetes insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tandem Diabetes'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Douglas Roeder over six months ago Purchase by Douglas Roeder of 300000 shares of Senseonics Holdings | ||
Douglas Roeder over six months ago Acquisition by Douglas Roeder of 200000 shares of Senseonics Holdings subject to Rule 16b-3 |
Tandem Diabetes Management Efficiency
The company has return on total asset (ROA) of (0.0963) % which means that it has lost $0.0963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5908) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to grow to -0.29. At this time, Tandem Diabetes' Intangible Assets are very stable compared to the past year. As of the 19th of April 2024, Net Tangible Assets is likely to grow to about 531.2 M, while Intangibles To Total Assets are likely to drop 0.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gary Guthart | Illumina | 52 | |
| Roy Whitfield | Illumina | 63 | |
| Michael Kelly | Mettler Toledo International | 64 | |
| George Llado | Charles River Laboratories | 55 | |
| Tadataka Yamada | Agilent Technologies | 74 | |
| Connie Harvey | Mettler Toledo International | 52 | |
| Robert Bertolini | Charles River Laboratories | 59 | |
| Sperling Sperling | Thermo Fisher Scientific | 58 | |
| Michael Berendt | Waters | 71 | |
| Robert Epstein | Illumina | 62 | |
| Dow Wilson | Agilent Technologies | 61 | |
| Richard Reese | Charles River Laboratories | 75 | |
| Christopher Kuebler | Waters | 66 | |
| George Massaro | Charles River Laboratories | 73 | |
| Bahija Jallal | Guardant Health | 56 | |
| Caroline Dorsa | Illumina | 58 | |
| Richard Francis | Mettler Toledo International | 52 | |
| Debora Spar | Thermo Fisher Scientific | 56 | |
| Philip Schiller | Illumina | 57 | |
| George Milne | Charles River Laboratories | 77 | |
| Hans Bishop | Agilent Technologies | 56 | |
Management Performance
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.0963 |
Tandem Diabetes Care Leadership Team
Elected by the shareholders, the Tandem Diabetes' board of directors comprises two types of representatives: Tandem Diabetes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tandem. The board's role is to monitor Tandem Diabetes' management team and ensure that shareholders' interests are well served. Tandem Diabetes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tandem Diabetes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tom Fox, Chief Officer | ||
| Rebecca Robertson, Independent Director | ||
| David Esq, Transitional Advisor | ||
| Libba Sapitsky, Senior Care | ||
| Dick Allen, Chairman of the Board | ||
| Douglas Roeder, Independent Director | ||
| Leigh Vosseller, Senior Vice President - Finance | ||
| Rick Carpenter, Chief Officer | ||
| Elizabeth Gasser, Executive Officer | ||
| Brian Hansen, Chief Commercial Officer, Executive Vice President | ||
| Fred Cohen, Independent Director | ||
| Susan Morrison, Chief Admin. Officer | ||
| Lori Gildea, Vice President - Sales | ||
| Howard Greene, Independent Director | ||
| Ross Sylvia, VP Marketing | ||
| Christopher Twomey, Independent Director | ||
| Jordan MD, Chief Officer | ||
| Henry Anhalt, Independent Director | ||
| Edward Cahill, Independent Director | ||
| Lonnie Smith, Chairman of the Board | ||
| John Cajigas, CFO and Executive VP | ||
| David Berger, General Counsel | ||
| Jesse Treu, Independent Director | ||
| Richard Valencia, Independent Director | ||
| John Sheridan, COO and Executive VP | ||
| Kim Blickenstaff, CEO and President and Director | ||
| Robert Anacone, Chief Commercial Officer and Executive VP | ||
| Shannon Hansen, Privacy Legal |
Tandem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tandem Diabetes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.0963 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 2.12 B | ||||
| Shares Outstanding | 64.56 M | ||||
| Shares Owned By Insiders | 0.60 % | ||||
| Shares Owned By Institutions | 99.40 % | ||||
| Number Of Shares Shorted | 9.31 M | ||||
| Price To Earning | 494.25 X |
Currently Active Assets on Macroaxis
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (3.43) | Revenue Per Share 11.509 | Quarterly Revenue Growth (0.11) | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.